Home

Transient Receptor Potential (TRP) Therapeutics—
A New Approach to Pain Treatment

Unlocking the TRP
Therapeutic Potential

Non-Opioid, Non-Addictive, Pain Therapeutics.

Algomedix is developing novel Transient Receptor Potential (TRP) therapeutics to treat serious unmet medical needs including acute and chronic pain and kidney disease.

Globe-Icon_Homepage_Mobile
Chronic pain affects up to 30 percent of the worldwide population.
Rx-Icon_Homepage_Mobile
Opioid prescriptions in U.S. have tripled in past 20 years.
Pill-Icon_Homepage_Mobile
Long-term opioid use is linked to addiction and side effects.

Multiple Targets. Multiple Opportunities.

Chronic Pain, Acute Pain, Kidney Disease, Asthma, Pulmonary Hypertension, Cough, COPD, Migraine, Cough, Ocular Pain, Ocular irritation, Nephrosis, Diabetic Neuropathy, Cardiac Hypertrophy, Bladder Hyperactivity, Painful Bladder Syndrome, Interstitial Cystitis

Discovery

Differentiated, Innovative TRP Research
Learn More >

Partnerships

Diverse & Novel Opportunities
Learn More >

Pipeline

Next-generation analgesic
Learn More >